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Mesenchymal stromal/stem cells (MSCs) reveal progenitor cells-like features including proliferation and differentiation capacities.
One of the most historically recognized sources of MSC has been the bone marrow, while other sources recently include adipose
tissue, teeth, bone, muscle, placenta, liver, pancreas, umbilical cord, and cord blood. Frequently, progenitor isolation requires
traumatic procedures that are poorly feasible and associated with patient discomfort. In the attempt to identify amore approachable
MSC source, we focused on endometrial decidual tissue (EDT) found within menstrual blood. Based also on recent literature
findings, we hypothesized that EDT may contain heterogeneous populations including some having MSC-like features. Thus,
we here sought to isolate EDT-MSC processing menstrual samples from multiple donors. Cytofluorimetric analyses revealed
that resulting adherent cells were expressing mesenchymal surface markers, including CD56, CD73, CD90, CD105 and CD146,
and pluripotency markers such as SSEA-4. Moreover, EDT-MSC showed a robust clonogenic potential and could be largely
expanded in vitro as fibroblastoid elements. In addition, differentiation assays drove these cells towards osteogenic, adipogenic,
and chondrogenic lineages. Finally, for the first time, we were able to gene modify these progenitors by a retroviral vector carrying
the green fluorescent protein. From these data, we suggest that EDT-MSC could represent a new promising tool having potential
within cell and gene therapy applications.
1. Introduction
Mesenchymal stromal/stem cells (MSCs) are adult progenitor
cells isolated from several human adult and perinatal tissues
[1, 2]. While the acronymMSC seems to equate the biological
properties of these useful progenitors, the possibility to isolate
these cells from different tissue has been outlining common
features combined with source-specific peculiarities that are
still under investigation.
MSC demonstrated a positive impact in several patholog-
ical conditions [1, 3, 4], exerting their therapeutic functions
on damaged tissues through different mechanisms, including
differentiation intomature cells and largely obscure paracrine
effects [5]. Moreover, MSCs have also been investigated for
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their possible use to deliver wild-type or gene modification-
induced bioactive molecules with promising, but still unde-
fined, influence in cancer models [6–9]. In the light of
these findings, it appears reasonable to propose that a tissue
source of MSC could be deemed relevant and useful by
determining if it provides cells with varied differentiation
potential and distinct cytokine profiles that may indicate
an advantageous role in the interaction with tumors [1,
10]. Therefore, understanding these features from distinct
MSC tissue sources shall be a primary objective to effi-
ciently translate these cells into different clinical applica-
tions.
One most recognized source of MSC has been the bone
marrow obtained from iliac crest and more recently, MSC
progenitors have been isolated from lipoaspirates and other
tissue sources including teeth, bone, muscle, placenta, liver,
pancreas, umbilical cord, and cord blood [11]. In the majority
of these cases, especially the autologous sources, tissue iso-
lation requires traumatic procedures sometimes linked with
patient’s discomfort.
In the attempt to identify a different and more approach-
able MSC source for cell and gene therapies, we focused on
endometrial decidual tissue (EDT) obtained from menstrual
blood. Previous cloning studies of isolated human endome-
trial cells provided early evidence of rare clonogenic mes-
enchymal cells, representing approximately 1% of endome-
trial cells suspension obtained by uterine tissue digestion
after hysterectomy [12]. These endometrial stromal elements
demonstrated properties similar to bonemarrow and adipose
tissue MSC including substantial self-renewal ability in vitro,
high proliferative potential, and multilineage differentiation
[13, 14]. However, obtaining these cells directly from endo-
metrium either after hysterectomy or by biopsy still implies
invasive procedures.
In order to evaluate the possibility of obtaining multi-
potent cells from the uterus by a non-invasive and repro-
ducible manner, researchers started to analyze shed men-
strual blood and tissue in the attempt to identify menstrual
blood-derived MSC [15, 16]. These pilot studies confirmed
what was already known for endometrial cells obtained from
hysterectomy, suggesting that endometrial stem/progenitor
cells may be shed in menstrual blood.
Following these early findings and by different isolation
steps, this study characterizes EDT as a novel tissue source
of MSC with regards to possible applications in regenerative
medicine and gene therapy.MSCs fromdifferent sources have
been investigated for their possible uses as tumor-specific
delivery vehicles for suicide genes, oncolytic viruses, or sec-
reted therapeutic proteins [8]. The mechanisms through
which MSCs are considered to home to tumors are not com-
pletely clear, but seem to be dependent on biological proper-
ties of tumor microenvironment as well as the native tropism
of selected MSC and also on the experimental procedures
used [10, 17].Thanks to genetic manipulation techniques, this
natural tropism has been recently and convincingly exploited
to transform MSC in “bullets” capable to deliver oncolytic
viruses or various anticancer agents directly into tumor sites
[8]. The possibility of having noninvasive procedures to
obtain autologous progenitor cells, although with a gender
limitation, paves the way to a more intense research activity
aimed to deeply characterize MSC from a different source for
selected biomedical applications.
2. Materials and Methods
2.1. Cell Procurement and Processing. Menstrual blood was
collected from healthy female volunteer donors (𝑛 = 3) dur-
ing the first few days of the cycle. Written consent was
obtained from each donor and the Local Ethical Committee
approved cells donation for research purposes. Each donor
has been endowed with a menstrual cup (DivaCup, Diva
International, San Francisco, CA, USA) to collect blood,
which was transferred in phosphate buffered saline (PBS,
PAA Laboratories, Pasching, Austria) with 1% penicillin/
streptomycin (10,000U/mL Penicillin, 10mg/mL Strepto-
mycin in 0.9% NaCl solution, PAA Laboratories), 35mg/mL
fluconazole (Diflucan, Pfizer, New York, NY, USA) and hep-
arin (500U/mL, Sigma, St. Louis, MO, USA). Samples were
maintained at 4∘C for 24–48 h after procurement until reach-
ing the processing laboratory.
The endometrial tissue, if present, was discarded, and the
remaining blood was homogenized by 20 passages through a
19G needle using a 10mL syringe. Cell suspension was then
cultured as below reported. In addition, two alternative iso-
lation protocols involving separation of the corpuscular frac-
tion of blood through normal or density-gradient centrifu-
gations were initially introduced. However, these latter two
approaches were discontinued because of poor isolation effi-
ciency (data not shown).
2.2. Cell Culture. Isolated cells were seeded into culture flasks
to obtain an adherent fraction by adding 𝛼MEM (Gibco),
1% L-glutamine (200mM in 0.85% NaCl solution, Lonza
Verviers, Belgium), 1%penicillin/streptomycin (PAALabora-
tories), and 10% fetal bovine serum (FBS; PAA Laboratories).
In addition, a serum-deprived medium (Quantum 333) with
1% penicillin/streptomycin was also introduced (all from
PAA Laboratories). Cells were cultured for 7 days, washed
with PBS (PAA Laboratories) to remove the nonadherent
fraction, and fresh medium was added. At confluence, cells
were detached by trypsin (trypsin 0.05% EDTA 0.02% in
PBS, EuroClone, Milan, Italy) and subcultured at a density
of 6000 cells/cm2 until functional assays. All flasks were incu-
bated at 37∘C, 5%CO
2
, andmediumwas changed every other
day.
2.3. Clonogenic Assay. Adherent cells, out of passage 1 (P1) or
passage 2 (P2), were seeded at clonal density of 100 cells/cm2
in 𝛼MEM (Gibco), 1% L-glutamine (Lonza), 1% penicillin/
streptomycin (PAA Laboratories), and 10% FBS (PAA Labo-
ratories). Colony formation was monitored daily. On day 10,
cells were fixed with cooled absolute methanol for 2 minutes
and stained for 5 minutes with 1% crystal violet aqueous
solution (Sigma). Colonies with more than 50 cells were then
counted, as originally described for marrow MSC [18]. Each
assaywas repeated in triplicate, and cloning efficiency (𝐸) was
calculated as 𝐸% = (n. clones/cells seeded) ⋅ 100.
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2.4. Proliferation Assay. Adherent cells were seeded at a
density of 6000 cells/cm2 in 𝛼MEM (Gibco), 1% L-glutamine
(Lonza), 1% penicillin/streptomycin (PAA Laboratories), and
10% FBS (PAA Laboratories) in different flasks for the
following time points: 24, 48, 72, and 96 hours. At each time
point, cells were trypsinized and counted. Data obtainedwere
plotted as number of harvested cells (𝑦) against hours of
culture (𝑥), and the exponential growth curve was generated
using GraphPad Prism software (GraphPad Software Inc.,
version 5.00). The doubling time (𝑇) was obtained from the
growth constant (𝑘) of the exponential equation 𝑦 = 𝑎 ⋅ 𝑒𝑘𝑥,
where 𝑘 = ln 2/𝑇.
2.5. Senescence-Associated 𝛽-Galactosidase Staining. To as-
sess cell senescence, the activity of 𝛽-galactosidase (𝛽-gal) at
pH 6 was evaluated. 𝛽-gal expression is a feature of senescent
cells [19]. According to Senescence 𝛽-galactosidase Staining
Kit (Cell Signaling Technology, Beverly, MA, USA), growth
medium was removed, and cells were washed with PBS (PAA
Laboratories). Cells were then incubated for 15 minutes with
a fixative solution (20% formaldehyde, 2% glutaraldehyde in
10x PBS) and washed twice with PBS (PAA Laboratories).
Color development was obtained by incubation overnight
at 37∘C with the provided staining solution (40mM citric
acid/sodium phosphate pH 6.0, 150mMNaCl, 2mMMgCl
2
,
5 nM potassium ferricyanide, and 1mg/mL X-gal in DMSO).
Plateswere then observed bymicroscopy for the development
of blue color.
2.6. FACSAnalyses. Adherent cells were harvested for surface
antigen analysis. Briefly, cells were detached from plastic sup-
port by trypsin (EuroClone), counted, and aliquoted in FACS
analyses polypropylene tubes (0.5–1 ⋅ 106 cells/tube) (VWR,
Milan, Italy). EDT-MSCs were subsequently incubated in
blocking buffer (100 𝜇L each 0.5–1 ⋅ 106 cells) containing
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco), 10%
FBS (PAA Laboratories), and 0.1M sodium azide and human
immunoglobulin G (both from Sigma) and incubated for
20󸀠 on ice. After a PBS (PAA Laboratories) washing step,
cells were resuspended in PBS (PAA Laboratories) with 0.5%
bovine serum albumin (BSA, Sigma) and stained on ice and
in the dark for 30󸀠 with the following monoclonal antibod-
ies: APC-anti-CD45, FITC-anti-HLADR, PE-anti-CD34, PE-
anti-CD14, and FITC-anti-CD56 (all from Becton Dickin-
son, Franklin Lakes, NJ, USA); PE-anti-CD31 (BioLegend);
APC-anti-CD90, PE-anti-SSEA-4 (both from eBioscience,
San Diego, CA, USA); FITC-anti-CD105, PE-anti-CD73 (all
from BD Pharmingen); APC-anti-CD146 (Miltenyi Biotec).
In all the experiments, the corresponding isotype-matched
antibodies were used as negative controls (BD Pharmingen
and Becton Dickinson). Data were collected using a FACS
Aria III flow cytometer (BD Biosciences) and analyzed on
FACS Diva software (BD Biosciences).
2.7. Multilineage Differentiation Assays. To assess in vitro
differentiation capacities, adherent cells after P2 were cul-
tured in specific induction media. Media were changed every
other day and undifferentiated controls were concurrently
cultured in 𝛼MEM (Gibco), 1% L-glutamine (Lonza), 1%
penicillin/streptomycin (PAA Laboratories), and 10% FBS
(PAA Laboratories) for the same incubation time. Each assay
was performed in triplicate.
Adipogenic, osteogenic, and chondrogenic differentia-
tions were performed as previously reported [20]. Briefly, for
osteogenic differentiation, cells were seeded at the density of
10000 cells/cm2 and maintained in the growth medium until
confluence. Culture medium was then substituted with the
induction one, composed by 𝛼MEM (Gibco) supplemented
with 10 nM dexamethasone (Sigma), 10mM 𝛽-glycerol phos-
phate (Sigma), 0.1mM L-ascorbic acid-2-phosphate (Sigma),
10% defined FBS (Hyclone, Logan, UT,USA), 1% L-glutamine
(Lonza), and 1% penicillin/streptomycin (PAA Laboratories).
Induction was maintained for 14 days and, from the seventh
day, 100 ng/mL BMP-2 (Peprotech, Rocky Hill, NJ, USA)
was added. Confirmation of osteogenic differentiation was
performed through Alizarin Red staining combined by real-
time qPCR analysis (described below). At the end of the
induction period, culture wells were washed briefly with
a buffer solution containing 20mM Tris-HCl and 150mM
NaCl in water. Cells were then fixed and dried with cooled
absolute methanol for 2 minutes. After a washing step with
ddH
2
O, cells were stained by 1.5% Alizarin Red aqueous
solution pH 4.0–4.2 (Sigma) for 5 minutes and washed again
firstwith ddH
2
Oand thenwith PBS (PAALaboratories) for 15
minutes. The last step consisted of dehydration using cooled
absolute ethanol for 2 minutes followed by microscopic
observation.
For adipogenic differentiation, EDT-MSCswere seeded at
the density of 10000 cells/cm2 and maintained in the growth
medium until confluence. The medium was then substi-
tuted with the induction one, composed of 𝛼MEM (Gibco)
supplemented with 1𝜇M dexamethasone (Sigma), 60 𝜇M
indomethacin (Sigma), 10𝜇M insulin (Sigma), 0.5mM 3-
isobutyl-1-methylxanthine (IBMX, Sigma), 10% rabbit serum
(EuroClone), 5% horse serum (EuroClone), 1% L-glutamine
(Lonza), and 1% penicillin/streptomycin (PAA Laboratories).
Induction lasted 10 days and confirmation of differentiation
was achieved through Oil Red O staining, as follows. Culture
wells were washed briefly with PBS (PAA Laboratories). Cells
were fixed with vapors of 37% formaldehyde (Sigma) for 10
minutes and then washed with water for 2 minutes. Staining
was obtained adding an Oil Red O solution (10mg/mL Oil
Red O in ethanol 70% and acetone; all from Sigma) into the
wells for 3 minutes. Excessive stain was removed by washing
with water and cells were then counterstained by Harris
hematoxylin (Bio-Optica, Milan, Italy) for 30 seconds.
Finally, for chondrogenic differentiation 2–5 ⋅ 105 EDT-
MSCs were aliquoted in a 2mL tube and then centrifuged
at 1200 rpm for 10 minutes. Cells were maintained pelleted
in the growth medium at 37∘C with the plug opened. After
2 days of incubation, tubes were centrifuged again, and the
medium was substituted with the induction one, composed
by 𝛼MEM (Gibco) supplemented with 100 nM dexametha-
sone (Sigma), 200𝜇M L-ascorbic acid-2-phosphate (Sigma),
100 𝜇g/mL sodium pyruvate (Biochrom AG, Berlin, Ger-
many), 40 𝜇g/mL proline (Sigma), 1x ITS+ premix (BD Bio-
sciences, San Jose, CA, USA), 10 ng/mL TGF-𝛽 (Peprotech),
0.5 𝜇g/mL BMP-6 (Peprotech), 1% L-glutamine (Lonza),
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Table 1: Primer sequences.
Gene Primer sequence Amplified length
𝛽-actin 5
󸀠-ACC TTC TAC AAT GAG CTG CG-3󸀠 (sense) 148 bp
5󸀠-CCT GGA TAG CAA CGT ACA TGG-3󸀠 (antisense)
ALP 5
󸀠-GAT GTG GAG TAT GAG AGT GAC G-3󸀠 (sense) 142 bp
5󸀠-GGT CAA GGG TCA GGA GTT C-3󸀠 (antisense)
COL1A2 5
󸀠-AGG ACA AGA AAC ACG TCT GG-3󸀠 (sense) 146 bp
5󸀠-GGT GAT GTT CTG AGA GGC ATA G-3󸀠 (antisense)
OC 5
󸀠-CAG CGA GGT AGT GAA GAG AC-3󸀠 (sense) 144 bp
5󸀠-TGA AAG CCG ATG TGG TCA G-3󸀠 (antisense)
ALP: alkaline phosphatase, COL1A2: collagen 1A2, OC: osteocalcin.
and 1% penicillin/streptomycin (PAA Laboratories). Before
and after each medium change, tubes were centrifuged at
1200 rpm for 10 minutes. During the incubation period, cells
remained as pellet with the tube plugs opened. Induction
lasted 21 days, and specimens were fixed for 1 hour in
10% formaldehyde (Sigma) and then dehydrated by serial
passages into ethanol at increasing concentrations, from 70%
to 100%. Samples were then included into paraffin blocks and
cut in slices on microscope slides for Alcian Blue staining.
Slides were deparaffinized with the Histo-C cleaning agent
(Celltech, Turin, Italy) and rehydrated through passages
into a decreasing concentration alcoholic ladder (from 100%
ethanol to 70%ethanol). Sample sectionswere then incubated
with a 0.5mg/mLHyaluronidase (Sigma) in buffer phosphate
solution (8 g/L NaCl, 2 g/L NaH
2
PO
4
, and 0.3 g/L Na
2
HPO
4
)
with 10mg/mL BSA (Sigma). Slides were washed in water for
5 minutes and then immersed in a 3% acetic acid solution
for few seconds. Staining with 10mg/mLAlcian Blue solution
in 3% acetic acid (pH 2.5, Sigma) lasted 30 minutes, and
after a washing step in water, samples were counterstained
for 5 minutes with nuclear fast red solution (Sigma) and then
washed in water.
2.8. Real-Time qPCR. Total cellular RNA was isolated from
osteogenic committed and uncommitted cells, using Trizol
reagent method (Invitrogen) according to manufacturer’s
instructions. Samples were concentrated by ethanol pre-
cipitation and suspended in RNase-free water. RNA quan-
tity was assessed by spectrophotometry (DU730 UV/VIS
Spectrophotometer; Beckman Coulter, Milan, Italy). A 2𝜇g
aliquot was reverse transcribed into cDNA using Rever-
tAid First Strand cDNA Synthesis Kit (Fermentas) by oligo
(dT)
18
primers in a final volume of 20 𝜇L. Reactions were
performed at 42∘C for 1 h with a final step at 70∘C for 5
minutes. cDNA was then used to determine the osteoblast-
associated gene expression by quantitative real-time PCR
technique using Step One Real-Time PCR System Thermal
Cycling Block (Applied Biosystems, Foster City, CA, USA).
Each sample was compared with noninduced control for
the expression of alkaline phosphatase, collagen 1A2, and
osteocalcin. 𝛽-actin was used as a reference gene. All primers
were purchased from Integrated DNA Technologies, and
sequences are reported in Table 1. PCR was performed with
Fast SYBR Green Master Mix (Applied Biosystems) which
uses AmpliTaq Fast DNA Polymerase, SYBR Green I dye
to detect double-stranded DNA, and ROX dye as a passive
internal reference. Reaction proceeded through an initial step
at 95∘C for 20󸀠󸀠, followed by 40 cycles of denaturation (3󸀠󸀠 at
95∘C), annealing, and extending (30󸀠󸀠 at 60∘C).The final stage
comprises the analysis of themelt curve through a denaturing
step (15󸀠󸀠 at 95∘C) followed by annealing (1󸀠 at 60∘C) and
ramping to 95∘C with 0.3∘C increment/step. Levels of mRNA
for tested genes were quantified using ΔΔCT method and
normalized against human 𝛽-actin as a housekeeping gene.
Data have been analyzed by StepOne software (version 2.1,
Life Technologies Corporation, Carlsbad, CA, USA).
2.9. Gene Modification of EDT-MSC. Cultured cells were
infected by a bicistronicmurine stem cell virus-derived retro-
viral vector (pMIGR1) encoding for green fluorescent Protein
(GFP). Retrovirus production was performed by the FLYRD
packaging cell lines, as published by Marx et al. [21]. FLYRD
cells were seeded in a T175 flask with 10mL of medium com-
posed by DMEM (Gibco) supplemented with 10% defined
FBS (Hyclone). Cell supernatant was collected and filtered
(PES) with a 0.45 𝜇m filter, and EDT-MSC were incubated
for 6 hrs with 5mL culture medium, composed by: 𝛼MEM
(Gibco), 1% L-glutamine (Lonza), 1% penicillin/streptomycin
(PAA Laboratories), and 10% FBS (PAA Laboratories) with
the addition of 5mL viral particles-containing supernatant
and 6 𝜇g/mL polybrene (Sigma). Cells were then washed by
PBS (PAA Laboratories) and culture medium was changed.
The infection step was repeated for three consecutive days
at which time cells were evaluated at FACS Aria III flow
cytometer (BD Biosciences) for GFP protein expression. 7-
amino-actinomycin D (7AAD) staining was also performed
to evaluate mortality after transduction. Cells were evaluated
by FACS Aria III (BD Biosciences), and data were analyzed
using FACS Diva software (BD Biosciences).
2.10. Statistics. Data are expressed as average values, and
analyses were performed by GraphPad Prism software. t-test
was considered as significant with 𝑃 value <0.05.
3. Results
3.1. EDT-Derived Cells Are In Vitro Heterogeneous but Retain
Predominant MSC Features. Adherent cells isolated from
menstrual blood initially displayed in vitro fibroblast shape
morphology in both 𝛼MEMwith 10% FBS and Quantum 333
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(Figures 1(a)-1(b)). However, prolonged cultures in 𝛼MEM
with 10% FBS showed a significant better growth perfor-
mance, and this medium was then preferentially used for
all subsequent functional analyses. Adherent elements had
typical mesenchymal aspect being fibroblastoid-like, spindle-
shaped cells with an elongated cytoplasm. Within this pop-
ulation, it was also possible to identify more infrequent
cell clusters with a distinct morphology. These appeared
as endothelial-like sometimes binucleated cells, forming a
monolayer with polygonal shape (Figure 1(c)). However, we
did not confirm the nature of this population, because their
presence disappeared after very early passages and because
they were not the subjects of this study.
3.2. EDT-Derived Cells Show Robust Clonogenic and Prolif-
erative Potential. Having observed the fibroblast shape of
EDT isolated cells, we then focused on their clonogenic and
proliferative potential. We observed a high clonal efficiency
with an average of 14.1% (10.8–17.9%) of the seeded cells
able to generating colonies. This result indicates that the
menstrual-derived cell population contains a large fraction
of actively cycling cells with signficant clonogenic potential
(Figure 2(a)). Of interests, colonies did not appear homoge-
nous, and we were able to identify at least two kinds of
morphologies. On the one hand, densely populated clones
constituted by small size cells (Figures 2(b)-2(c)) and on
the other, smaller cell clusters with elements having a large
cytoplasm with an evident cytoskeleton (Figures 2(d)-2(e)).
Isolated and expanded cells also demonstrated surpris-
ingly low doubling time, with an average value of 27.6 hours
(21.9–33.0) (Figure 3). The high number of passages that
these cells were able to reach, further supported this remark-
able growth property. The 𝛽-galactosidase staining, per-
formed to evaluate senescent cells, showed that cells cul-
tured in Quantum 333 underwent senescence at passage 17,
while those cultured in 𝛼MEM supplemented with 10% FBS
reached passage 26 before growth arrest (Figures 4(a)–4(d)).
Together these data suggest how plastic-adherent, fibroblast
shaped cells from EDT retain a strong proliferative potential
comparable or even superior to MSC from other sour-
ces.
3.3. EDT-Derived Cells Display MSC Phenotypic Features.
Having evaluated the proliferation potential and to more
carefully define the MSC nature of isolated and expanded
cells, we assessed their antigen expression profile. EDT-
derived cells express typical MSC markers (Figures 5 and 6),
and in particular more than 90% of tested cells were posi-
tive for CD90 and CD73, constituting main features of MSC
from other sources [22]. We also observed that more than
80% of cells expressed CD146, an adhesion molecule related
but not restricted to MSC and also expressed by endothe-
lial cells [1]. The levels of CD45, HLADR, CD31, and CD14,
assessed early in culture and commonly used to distinguish
MSC from hematopoietic and endothelial cells, were below
2% in most cases. In sample 1, we observed a slightly increase
in the CD45+ fraction, suggesting the presence of hematopoi-
etic elements which might have been isolated together with
EDT-MSC. Other markers were also considered, such as
CD56 whose positivity was extremely variable by up to 45%.
Collectively, EDT-MSC from different donors showed the
same overall trend in markers expression (Figure 6), despite
for some markers, such as for CD56, CD105, and CD146,
the variability has been considerably high. The phenotypic
heterogeneity was also confirmed by analysis of physical
parameters by FACS. Forward scatter versus side scatter plot
was very dispersed, and it was impossible to identify consist-
ent cell groupswith similar physical parameters. Interestingly,
we have to report a consistent small fraction (>1.0%) of SSEA-
4 positive cells that reached 19.4% suggesting the expression
of a pluripotency marker in this MSC type.
3.4. EDT-MSCs Are Precursors of Three Mesenchymal Tissues
In Vitro . FACS analyses were then followed by assays aim-
ing to assess EDT-MSC multipotency. We first focused on
adipose commitment and, after 10 days of adipogenic induc-
ing cocktail, EDT-MSCs were able to differentiate into vacu-
ole-producing elements. The Oil Red staining confirmed
the lipid content of those cells indicating the fat-producing
ability of isolated and induced cells (Figure 7(a)). Osteogenic
medium was then applied for 14 days, and cells underwent to
osteoblastic commitment, forming a compact calcifiedmatrix
with calcium deposits confirmed by specific Alizarin Red
staining (Figure 7(b)). Finally, after 21 days of chondrogenic
induction, pellets of EDT-MSCs were included into paraffin
blocks, and Alcian Blue highlighted the sulfated proteogly-
cans expression typical of the cartilaginousmatrix, while Fast
Red staining revealed the nuclei of resident chondrocytes
derived from EDT-MSC (Figure 7(c)). Since a main focus of
our research group is bone regeneration, we then coupled
the cytochemical assay of osteogenic induced EDT-MSCwith
qPCR to further confirm bone commitment. As seen in
Figure 8, all tested genes demonstrated an increased expres-
sion in induced samples versus noninduced controls. In part-
icular, in osteoblast-induced cells the expression of alkaline
phosphatase resulted 45 times higher (𝑃 < 0.0001), while
more modest increases were observed for collagen 1A2 (2.9
times; 𝑃 < 0.05) and osteocalcin (2.1 times; 𝑃 < 0.05). These
findings, together with positive Alizarin staining, reinforced
the evidence for commitment of induced EDT-MSC to func-
tional osteoblasts.
3.5. EDT-MSC Can Be Efficiently Gene Modified. To explore
whether ex vivo expanded EDT-MSC could be genetically
manipulated for future gene delivery approaches, cells were
incubated with supernatants containing retroviral particles
carrying the GFP gene. As shown in Figure 9, RD114 pseu-
dotyped retroviral particles were able to efficiently and stably
transduce EDT-MSCwith levels greater than 80%, suggesting
how this MSC type could be suitable for gene delivery
approaches.
4. Discussion
SeveralMSC types have been obtained starting from different
sources; here, we have isolated a population of mesenchymal
progenitors from menstrual EDT and characterized them
both at morphological and molecular levels investigating
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(a) (b)
(c)
Figure 1: In vitro adherent cells from decidual tissues. (a) Representative photomicrograph of spindle-shaped adherent cells isolated by
𝛼MEM and 10% FBS. (b) Cells isolated in vitro by serum-deprived medium (Quantum 333) at early passages. (c) Another population of cells
was in vitro isolated contextually with EDT-MSC.These elements share similarities with endothelial cells forming a monolayer of polygonal,
sometimes binucleated cells. Original magnification 100x.
their ability to proliferate, to differentiate, and to be gene
modified. EDT-MSCs appear as a heterogeneous cells pop-
ulation that can be safely and easily isolated by noninvasive
manner, providing an expandable source of cells. In culture,
they show mesenchymal morphology and, although some
studies suggest they could derive from bone marrow [23],
EDT-MSCs are generally considered to originate from the
shedding of endometrial stem/progenitor cells which are
mainly resident both in the basalis layer and, partially, in the
functionalis area of endometrium [24].
The presence of a uterine population of progenitor cells
would be consistent with the high tissue turn-over after each
menstrual cycle. However, it is still uncertain howmany sub-
populations of progenitors are present in the endometrium
and what are their specific properties. Therefore, in this pilot
study, we began by addressing the existence of mesenchymal
progenitors in the decidual endometrial tissue.
The initial in vitro approach was performed to evaluate
the clonogenic potential of these cells. EDT-MSC seeded at
clonal density revealed the presence of two distinct colony
types which closely resembled the stromal cell clones isolated
by Chan et al. from endometrium after hysterectomy [12].
One was composed of smaller and densely packed cells, and
the other was composed of larger and sparser elements. This
finding seems peculiar for EDT-MSC and differs from col-
onies established from BM-MSC that appear larger and
characterized by a central nucleus of cells surrounded by a
crown of more sparse ones [18]. Next to qualitative evalua-
tions of the colonies, our data suggest an average EDT-MSC
clonogenic efficiency of 14%. This value is higher than what
is described for BM-MSC and more similar or even superior
to what reported for AT-MSC that retained around 10% of
clonogenic precursors [25] (Table 3). In addition, our EDT-
MSC population seemed to have a higher clonogenic effi-
ciency compared to those described by other groups dealing
with endometrial stromal cells whose values ranged from 1
to 11% [12, 24, 26]. While this may be due to donor-related
issues such as age, in vitro technical aspects including harvest-
ing and preservation procedures that may also drive these
differences. Dimitrov et al. observed a tendency for these cells
to decrease in clonal efficiency with the increase of seeding
density [26]. Similarly, other culture conditions may generate
better performing EDT-MSC. In this pilot study, we tested
two different growthmedia, such as𝛼MEMwith 10%FBS and
a serum deprived medium. Although these cells apparently
did not shown particular nutritional requirements, serum-
containing medium proved to be the best choice, ensuring a
better morphological appearance and an improved longevity.
Previous studies reported the use of different media such as
DMEM/F-12 and Chang complete media often supplemented
with calf serum, hormones, and growth factors [12, 14, 26, 27].
This wide range of culture conditions is likely to impact the
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Figure 2: EDT-MSC clonogenic precursors. (a) A representative T-25 culture flask with crystal violet-stained EDT-MSC colonies. (b) and
(c) EDT-MSC compact clones with small size cells. (d) and (e) EDT-MSCs could also generate less populated colonies with larger cellular
elements. Original magnification 50x.
×10
5
25
20
15
10
5
0
C
el
l y
ie
ld
0 24 48 72 96 120
Time (h)
Sample 1
Sample 2
Sample 3
Figure 3: EDT-MSC proliferation. Cell proliferation assays performed to assess EDT-MSC doubling time. Doubling time for sample 1 was
33.0 h, for sample 2 was 21.9 h, and for sample 3 was 27.9 h.
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Figure 4: 𝛽-galactosidase staining. (a) Activity of 𝛽-galactosidase at pH 6 was assessed on passage 3 EDT-MSC cultured in FBS resulting
almost negative for the presence of typical blue senescent cells.The conspicuous number ofmitotic event is also visible, highlighting an intense
proliferative activity. (b) Cells grown in Quantum 333 underwent senescence at passage 17 and resulted in deep blue staining within most of
the amplified EDT-MSC. (c) Cells cultured in FBS were capable to reach passage 26 before showing senescence features, such as blue staining,
large cytoplasm, multinucleated elements, and evident cytoskeleton. (d) A detail of a senescent cell. Original magnification 100x.
in vitro behavior, leading to different performance in ex vivo
pivotal parameters.
Using a FBS-based medium, EDT-MSC demonstrated a
remarkable proliferation rate rapidly doubling their number
in less than 28 hrs. This result agrees with other similar
studies, which reported a doubling time between 18 and 36 h
for EDT-MSC [15, 28]. As seen in Table 3, similar attitude has
been also reported for dental pulp stem cells (DPSCs) and
umbilical cord (UC) MSC that duplicate in approximately
30 hrs, considerably faster versus both BM-MSC and AT-
MSC [29–31].
Beside this robust proliferative attitude, we also observed
that plastic adherent fraction from shedded DT could be
expanded for more than 25 passages before reaching senes-
cence, a result once again higher than what reported forMSC
from other sources. As summarized in Table 3, BM-MSC
and AT-MSC senescence has been reported from passages
7 and 8 [32], while UC-MSC grow longer in culture, until
passage 16 [31]. These findings reinforce the hypothesis that
EDT-MSC can duplicate for long time before senesce and are
consistent with reports asserting 25–30 population doublings
for uterine-derived precursors [15, 28, 33].This unique feature
fit well with the high rate of renewal retained in vivo by the
endometrium, leading to the conclusion that this new MSC
source could have a tremendous potential for large-scale clin-
ical applications in regenerative medicine.
In this work, EDT-MSC showed other similarities with
MSC from the other sources and, in particular, under the
immunophenotypical point of view satisfying recognized
phenotypic criteria for MSC [22]. The biomarker profile, as
compared in Table 2, shows a close resemblance of EDT-
MSC with other sources MSC, expressing high levels of
CD73 and CD90 and being negative for CD14, CD45, CD31,
and HLA-DR. Other markers have been additionally eval-
uated. CD56, also known as neural cell adhesion molecule
(NCAM), is a glycoprotein expressed by neuroectodermal-
derived cells such as neurons and glia but also by skeletal
muscle, NK cells and activated T cells [34]. Among our EDT-
MSC, CD56 expression has been extremely variable (1.3–
45%), and this may support the observation made by others
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Figure 5: EDT-MSCs express typicalMSCmarkers. Representative FACS analyses of EDT-MSC immunophenotype. Percentages are referring
to the average positivity for each marker. Cells were gated out of 7-AAD positivity to exclude nonviable elements.
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Table 2: Immunophenotype of MSC from different sources.
Marker CD14 CD45 CD73 CD90 CD105 CD146 CD31 HLA-DR References
BM-MSC − − +++ +++ +++ ++ − − [43, 44]
PB-MSC − − N/A +++ ++ N/A − − [45]
DPSC − − +++ +++ +++ N/A − − [30]
UC-MSC − − +++ +++ +++ N/A − − [2, 43]
AT-MSC − − +++ +++ ++ N/A − − [2, 43]
EDT-MSC − − +++ +++ ++ +++ − − ‡
Comparison between positive and negative MSC surface markers from different sources, including EDT-MSC. Variable expression is highlighted with ±. BM-
MSC: bone marrow MSC; PB-MSC: peripheral blood MSC; DPSC: dental pulp stromal cells; UC-MSC: umbilical cord MSC; AT-MSC: adipose tissue MSC;
EDT-MSC: decidual tissue MSC. ‡Original data from this study, references.
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Figure 6: Overall EDT-MSC antigens expression after passage 1 in
vitro. Marker expressions are here reported as average percentage
(±standard deviation) of each tested sample.
exploiting CD56 expression to discriminate distinct marrow
MSC subpopulations [35, 36]. Moreover, we evaluated the
expression of SSEA-4, a glycolipid recently proposed to be
a novel marker for BM-MSC isolation and that is expressed
by teratocarcinoma cells and embryonic stem cells [37].
EDT-MSC demonstrated a noticeable expression of SSEA-
4 that, while reaching 19.4% appeared far from the 90%
positivity reported by others on decidual-derived cells [15].
However, different laboratories reported discrepancies on
EDT-MSC phenotype [15, 28, 38], and this could be likely due
to the heterogeneity of menstrual blood cell population, to
differences in cell selection and, as stated, to culture condi-
tions [13]. In addition, the relatively short time from the early
evidence of these progenitors does not help in the pheno-
typical standardization and certainly will require deeper and
multicentric studies.
Multipotency is another key feature ofMSCs and all EDT-
MSC lines showed the in vitro capacity to differentiate into
threemesodermal lineages, such as osteoblast able to generate
mineralized matrix, lipid vacuole-containing adipocyte and
matrix-producing chondrocytes. Additional experimentswill
be necessary to confirm this ability, prompting their broad
introduction in regenerativemedicine applications. However,
we have here begun to assess the capacity of these cells
for robust osteogenic commitment confirmed by the differ-
entiation data obtained by staining for mineralized matrix,
we observed a relevant increase in the expression of typical
osteoblast-associated genes such as alkaline phosphatase,
osteocalcin, and collagen 1A2.
Regenerative therapies based on stem cells, and more
specifically on MSC infusion, may counteract tissue-losing
states and may also be useful to substitute the congenital
abnormal stem cell compartment in order to regenerate
healthy functional cells. In this perspective, ease of supply,
wide window of harvesting, and availability of EDT-MSC
would allow autologous or, ultimately, allogeneic EDT-MSC
transplantation. These properties have already been explo-
ited, and EDT-MSC have demonstrated a therapeutic effect
in a murine model of muscular dystrophy [38] and a neuro-
protective effect in an experimental stroke model [27]. More-
over, endometrial-derived cells seem to have robust anti-
inflammatory and immunomodulatory properties similarly
to other MSCs [27, 39]. For this reason they were intraven-
ously and intrathecally transplanted in 4 patients with mult-
iple sclerosis, notably without arising immunological reac-
tions or other adverse effects and with a clinical benefit that
shall be carefully assessed [40].
Another original result we here report is the high trans-
duction efficiency of EDT-MSC by a GFP-carrying retroviral
vector. The procedure generated exogenous gene expression
in more than 80% of the cells and, to our knowledge, this is
one of the first reports of such highly efficient genetic mani-
pulation of EDT-MSC by a single GFP-carrying vector pro-
viding a basis for use of these cells in gene therapy approaches,
including targeted cancer treatment or their use as cell vec-
tors for peptides or trophic factors. Having extensively cha-
racterized EDT-MSC,we presume that these cellsmay be use-
ful for a more efficient delivery of proapoptotic molecules
thanks to the high transduction efficiency and the rapid pro-
liferation.Thismay allow amore targeted approach andbetter
persistence of the cells in the tumor microenvironment.
Starting from these findings, future studies shall focus
on the characterisation of the heterogeneous cell populations
identifiable in menstrual decidual tissue, investigating the
existence of different progenitor subtypes as well as under-
standing the origin of these cells. More reliable techniques to
isolate and cultivate pure populations of EDT-MSC should be
developed and standardized in parallel to allow a rapid intro-
duction of this promising therapeutic tool into the clinic.
BioMed Research International 11
100x 100x 200x
Control Induced
(a)
50x 50x 100x
(b)
100x 100x 200x
(c)
Figure 7: EDT-MSCs differentiate into committed mesenchymal tissues. (a) Oil Red O staining in adipogenic induced and control EDT-
MSC. The red-brown vacuoles demonstrate differentiation into fat-producing cells. Original magnification 100x. (b) Alizarin Red staining
showing calcium deposits in induced cells when compared with noninduced controls. Original magnification 50x. (c) Alcian Blue staining
outlining sulfated proteoglycans expression suggesting differentiation into a chondrogenic tissue. Original magnification 100x.
Table 3: Growth characteristics of MSC from different sources.
Cell type Source Isolation yield Doubling time Clonogenic efficiency Senescence passage
BM-MSC Bone marrow aspirate 60–600 cells from 1mL of blood [41] 61.2 h [29] 3.9%∗ 7 [32]
PB-MSC Peripheral blood 1 to 13 MSC from 1 million ofmononuclear cells [11] N/A N/A N/A
DPSC Deciduous and adult teeth N/A 30 h [30] N/A N/A
UC-MSC Umbilical cord of newborns 5 ⋅ 10
4–5 ⋅ 105 cells from 1 cm3 of
umbilical cord tissue [42] 24 h [31] N/A 16 [31]
AT-MSC Liposuction, lipectomy, andlipoplasty 5 ⋅ 10
3 cells from 1 g of tissue [11] 45.2 h [29] 10% [25] 8 [32]
EDT-MSC Decidual tissue Variable‡ 27.6 h‡ 14.4%‡ 26‡
Comparison between growth parameters of MSC from different sources. BM-MSC: bone marrow MSC; PB-MSC: peripheral blood MSC; DPSC: dental pulp
stromal cells; UC-MSC: umbilical cordMSC; AT-MSC: adipose tissueMSC; EDT-MSC: decidual tissueMSC.∗Unpublished data; ‡original data from this study,
references.
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Figure 8: qRT-PCR for osteoblast-associated genes. The relative quantity of osteoblast-associated transcripts in induced EDT-MSC versus
noninduced controls revealed an increased expression of the considered markers. All values were statistically significant (𝑃 < 0.05). ALP:
alkaline phosphatase, COLL1A2: collagen 1A2, and OC: osteocalcin.
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Figure 9: GFP expression of transduced andwild-type EDT-MSC. Representative FACS analyses assessingGFP positivity of wild-type control
and transduced EDT-MSC.
5. Conclusions
This work highlights crucial features of a novel and still not
completely understood population of mesenchymal progeni-
tors isolated form endometrial decidual tissue. Cells grown
in vitro were characterized by a rapid proliferation, a high
clonogenic potential and a long-term survival. Advantages
in comparison with MSC from other sources include a
greater ease of supply and the protracted availability during a
woman’s lifetime with the additional benefit of deriving stem
cells from a waste tissue, thus avoiding critical ethical issues.
In the light of their capacity to differentiate intomesenchymal
tissues and their propensity to undergo geneticmanipulation,
EDT-MSCs hold promise for novel therapeutic approaches
for still incurable and highly disabling diseases.
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